Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-05 |
2024-09 |
-0.1 |
N/A |
N/A |
N/A |
2024-08-01 |
2024-06 |
-0.1 |
-0.11 |
-0.01 |
-10.00% |
2024-05-02 |
2024-03 |
-0.1 |
-0.1 |
N/A |
N/A |
2024-02-29 |
2023-12 |
-0.12 |
-0.12 |
N/A |
N/A |
2023-11-07 |
2023-09 |
-0.12 |
-0.12 |
N/A |
N/A |
2023-08-03 |
2023-06 |
-0.12 |
-0.1 |
0.02 |
16.67% |
Date |
Firm |
Action |
From |
To |
2023-09-11 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-03 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-03 |
Chardan Capital |
Upgrade |
Buy |
Buy |
2023-07-10 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-05 |
JMP Securities |
Upgrade |
Market Outperform |
Market Outperform |
2023-06-21 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-01-31 |
COLLIER WILLIAM H. |
Chief Executive Officer |
216.50K |
Stock Award(Grant) |
2024-02-01 |
HASTINGS DAVID C |
Chief Financial Officer |
181.91K |
Sale |
2023-01-31 |
HOWARD ELIZABETH ANN |
Officer |
86.02K |
Stock Award(Grant) |
2024-08-13 |
MANCHESTER KEITH S |
Director |
46.07K |
Sale |
2024-02-01 |
MC ELHAUGH MICHAEL JOHN |
Chief Executive Officer |
1.50M |
Sale |
2018-11-27 |
MURRAY MARK J |
Director |
341.40K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
9.97M |
22.93M |
5.95% |
2023-06-29 |
Two Seas Capital Lp |
8.28M |
19.05M |
4.94% |
2023-06-29 |
Whitefort Capital Management, LP |
8.09M |
18.62M |
4.83% |
2023-06-29 |
Vanguard Group Inc |
5.82M |
13.38M |
3.47% |
2023-06-29 |
Morgan Stanley |
5.08M |
11.68M |
3.03% |
2023-06-29 |
Rubric Capital Management LP |
3.40M |
7.81M |
2.03% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.30M |
7.59M |
1.97% |
2023-08-30 |
iShares Russell 2000 ETF |
2.73M |
5.54M |
1.63% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.61M |
3.70M |
0.96% |
2023-07-30 |
Fidelity Small Cap Index Fund |
1.09M |
2.37M |
0.65% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
861.37K |
1.75M |
0.51% |
2023-06-29 |
Morgan Stanley Inst Fund Inc-Inception Port |
750.71K |
1.73M |
0.45% |
Split |
Date |
0.2 : 1 |
2010-11-04 |